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A B S T R A C T
Purpose
Limited data are available on the time course of treatment failures (recurrence and/or death), the
nature and duration of adjuvant treatment benefit, and long-term recurrence rates in patients with
resected stage II and III colon cancer.
Methods
The data set assembled by the Adjuvant Colon Cancer Endpoints Group, a collection of individual
patient data from 18 trials and more than 20,800 patients testing fluorouracil-based adjuvant
therapy in patients with stage II or III colon cancer, was analyzed.
Results
A significant overall survival (OS) benefit of adjuvant therapy was consistent over the 8-year
follow-up period. The risk of recurrence in patients treated with adjuvant chemotherapy never
exceeds that of control patients, signifying that adjuvant therapy cures some patients, as opposed
to delaying recurrence. After 5 years, recurrence rates were less than 1.5% per year, and after 8
years, they were less than 0.5% per year. Significant disease-free survival (DFS) benefit from
adjuvant chemotherapy was observed in the first 2 years. After 2 years, DFS rates in treated and
control patients were not significantly different, and after 4 years, no trend toward benefit was
demonstrated. This benefit was primarily driven by patients with stage III disease.
Conclusion
Adjuvant chemotherapy provides significant DFS benefit, primarily by reducing the recurrence
rate, within the first 2 years of adjuvant therapy with some benefit in years 3 to 4, translating into
long-term OS benefit. This reflects the curative role of chemotherapy in the adjuvant setting. After
5 years, recurrence rates in patients treated on clinical trials are low, and after 8 years, they are
minimal; thus, long-term follow-up for recurrence is of little value.
J Clin Oncol 27:872-877. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Approximately 145,000 new patients with colorectal
cancer are diagnosed annually in the United States.
When diagnosed at a stage when curative surgical
resection is possible, fluorouracil (FU)-based adju-
vant chemotherapy for colon cancer has repeatedly
been shown to improve patient overall survival
(OS). FU with leucovorin became standard of care
for patients with stage III and selected stage II colon
cancer in the early 1990s1-4 and provided the basis
for the addition of oxaliplatin, which has been dem-
onstrated to further improve disease-free survival
(DFS) and OS in stage III patients.5,6 Although ad-
juvant chemotherapy is routinely administered for
only a limited duration of time (usually 6 months), it
apparently leads to long-term benefits in outcome,
usually measured in terms of 3- and 5-year rates of
OS or DFS.
Graphical presentations of survival or recur-
rence data from clinical trials, typically presented
using Kaplan-Meier plots, convey information re-
garding the absolute rate of recurrence, DFS, and OS
at any given time point. However, these plots do not
readily convey the risk of an event at a specific time
point, and a separation in survival curves does not
convey the interpretation of an early advantage
that is maintained over time as opposed to a con-
tinued difference in the relative risk of an event.
Therefore, the clinical demonstration of actual
cure of patients by adjuvant therapy is poorly
understood, both in colorectal cancer and in
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other solid tumors. More detailed information on the time course
of recurrence, such as both short- and long-term year-by-year
failure rates stratified by untreated and treated patients, may assist
in patient counseling and in determining follow-up recommenda-
tions. Furthermore, such analyses also provide information on the
long-standing question of whether adjuvant therapy in colon can-
cer completely eradicates tumor cells, thus allowing for higher cure
rates, or whether treatment only delays tumor recurrence. On the
basis of individual patient data from 20,898 patients randomly
assigned on 18 trials of adjuvant therapy for colon cancer, we
studied the time course of treatment failure and long-term recur-
rence rates.
METHODS
The data set assembled by the Adjuvant Colon Cancer Endpoints (ACCENT)
Group was used for all analyses.7 As previously described, ACCENT identified
and obtained individual patient data from 18 phase III adjuvant trials in colon
primary tumors conducted from 1978 to 1999. A total of 20,898 patients and
43 distinct treatment arms (34 active treatment arms and nine surgery-only
arms) are included in the ACCENT database. Table 1 and Appendix Table
A1 (online only) list the details regarding the trials and patient character-
istics, respectively.
This analysis focused on continuous time estimation of the hazard rate
(risk of recurrence or death) by treatment over time, as well as the continuous
time estimation of the hazard ratio (HR) comparing FU-based treatment with
control. The continuous time estimation of these rates and ratios allows the
risk of an event (for hazard rates) and benefit of treatment (for HRs) to vary
over time. This is in contrast to the usual estimated HR from a Cox propor-
tional hazards regression, which assumes that the HR between the two treat-
ment arms has a single value that is constant over time. Hazard rates over time
were estimated by the method of Müller and Wang.8 HRs, with 95% pointwise
CIs, were estimated using the method of Gilbert et al.9 The end points of OS,
DFS, and time to recurrence (TTR) were considered. OS is defined as time to
death from any cause. DFS is defined as the time to recurrence or death,
whichever occurs first. TTR is defined as the time to disease recurrence, where
deaths without recurrence were censored at the time of death. Recurrence was
defined only by a reappearance of primary colon cancer; second primary colon
cancers or other noncolon cancers were not classified as recurrences. Because
the definitions of these terms (DFS and TTR) were not consistent across all
included trials, the definitions here may differ from those used in the original
trial. The analysis of the overall treatment benefit was performed with a
log-rank test comparing treatment with control, stratified by the original trial.
Analyses comparing FU-based treatment with control were limited to
the nine trials with a no-treatment control arm (n  4,922; National Surgical
Adjuvant Breast and Bowel Project [NSABP] C-01 and C-02, North Central
Cancer Treatment Group [NCCTG] 784852, Fédération Francophone de
Cancérologie Digestive, Intergroup 0035, Interdisciplinary Group for Cancer
Care Evaluation, NCCTG 874651, Siena, and National Cancer Institute of
Canada trials in Table 1). Because of inconsistent long-term follow-up for the
hazard rate and HR analyses, all patients were censored at 8 years for analysis of
treatment benefit. Long-term event rates were estimated using data from all
trials where the median follow-up time for living patients exceeded 9 years
(eight trials, n  11,615; NCCTG 784852, Intergroup 0035, Intergroup 0089,
and NSABP C-01, C-02, C-03, C-04, and C-05 trials in Table 1).
RESULTS
Hazard Rates
Of the 20,898 patients, 35% experienced recurrence and 38%
died in the initial 8-year follow-up period. Sixty-six percent of patients
had stage III disease, and 33% had stage II disease. When the analyses
were restricted to the 4,922 patients on trials in which they were
randomly assigned to adjuvant treatment versus surgery alone, 1,670
patients (34%) experienced recurrence, and 1,910 patients (39%)
died. Traditional Kaplan-Meier plots of OS by stage for patients ran-
domly assigned to treatment versus control are presented in Figure 1.
To provide additional insight into the time-related nature of
adjuvant therapy benefit, hazard rates over time for OS, DFS, and TTR
by treatment group are shown in Figure 2. For both treated and
untreated patients, the risk of death from any cause (Fig 2A) peaks at
approximately 2 years after surgery and gradually declines over the
8-year estimation period. For the DFS and TTR end points (Figs 2B
and 2C), in untreated patients, the risk of an event clearly is highest in
the year after surgery, with a rapid reduction until approximately year
4. The failure rate in treated patients is low initially and then increases
in years 1 to 3, only to recede close to the rate in untreated patients by
year 4. The DFS curves (Fig 2B) remain slightly separated in years 4 to
8 between treatment and control, whereas the TTR curves (Fig 2C) are
virtually superimposable in that time period. For none of the end
points does the failure rate for treated patients ever exceed that of the
untreated patients during the 8-year follow-up period.
These patterns of treatment failure over time are substantially
different for stage II and stage III patients (Fig 3). In stage III patients,
the absolute risk of a DFS event is greater than for stage II patients in
the first 4 years of follow-up, becoming similar after years 5 to 6 as the
DFS end point becomes dominated by death events. In addition, the
relative benefit of treatment is considerably larger in stage III patients,
with a longer duration of benefit. In stage II patients, the modest early






NSABP C-01 1977-1983 Control v MOF 724
NCCTG 784852 1978-1984 Control v FU/LEV 247
FFCD 1982-1990 Control v FU/LV 239
NSABP C-02 1984-1988 Control v PVI FU 896
INT 0035 1984-1987 Control v FU/LEV 926
Siena 1985-1990 Control v FU/LV 256
NCIC 1987-1992 Control v FU/LV 359
NSABP C-03 1987-1989 MOF v FU/LV 1,042
NCCTG 874651 1988-1989 Control v FU/LV 408
GIVIO 1989-1992 Control v FU/LV 867
NCCTG 894651 1989-1991 FU/LV  LEV for 6 or 12 months 915
NSABP C-04 1989-1990 FU/LEV v FU/LV v FU/LV/LEV 2,083
INT 0089 1990-1992 FU/LEV v FU/LV (HD or LD) v
FU/LV/LEV
3,561
NSABP C-05 1991-1994 FU/LV v FU/LV  IFN 2,136
NCCTG 914653 1993-1998 FU/LV  HD or standard LEV 878
SWOG 9415 1994-1999 Bolus v infusional FU/LEV/LV 939
QUASAR 1994-1997 FU/LV (HD or LD)  LEV 3,517
GERCOR 1996-1999 Bolus v infusional FU/LV 905
Total 20,898
Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project;
MOF, semustine, vincristine, and fluorouracil; NCCTG, North Central Cancer
Treatment Group; FU, fluorouracil; LEV, levamisole; FFCD, Fédération Fran-
cophone de Cancérologie Digestive; LV, leucovorin; PVI, protracted venous
infusion; INT, Intergroup; NCIC, National Cancer Institute of Canada; GIVIO,
Interdisciplinary Group for Cancer Care Evaluation; HD, high dose; LD, low
dose; IFN, interferon alfa-2a; SWOG, Southwest Oncology Group; QUASAR,
Quick and Simple and Reliable Collaborative Group; GERCOR, French Multi-
disciplinary Clinical Research Group.
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benefit in reducing DFS events is entirely absent after 2 to 3 years,
whereas in stage III patients, it remains for at least 4 years.
HRs (with 95% pointwise CIs) comparing patients on the treat-
ment versus control arms of trials, plotted on the logarithmic scale, for
the OS, DFS, and TTR end points are shown in Figure 4. Figure 4A
demonstrates that the addition of adjuvant therapy provides a consis-
tent and durable beneficial effect on OS over the follow-up period,
with an estimated log-HR of0.30 (HR0.74) that is consistent over
time. In contrast, in Figures 4B and 4C, there is a substantial benefit of
adjuvant therapy in reducing the risk of a DFS or recurrence event the
first 1 to 2 years after resection (estimated log-HR in the range of
0.50; HR  0.61) that diminishes over time and becomes nonsignif-
icant (based on 95% pointwise CIs) after year 4, signifying that the
DFS and recurrence rates are statistically similar between treatment



























8-year OS Rate (95% CI): 54.3% (52.2% to 56.4%)
Surgey + FU-Based Chemotherapy



























8-year OS Rate (95% CI): 66.8% (63.7% to 70.0%)
Surgey + FU-Based Chemotherapy



























8-year OS Rate (95% CI): 42.7% (39.9% to 45.7%)
Surgey + FU-Based Chemotherapy
8-year OS Rate (95% CI): 53.0% (50.2% to 55.9%)
Fig 1. Kaplan-Meier plots of overall survival (OS) in treatment arm versus















































Fig 2. Hazard rates by time from random assignment and treatment arm. Plots
of the hazard rate for (A) overall survival, (B) disease-free survival, and (C) time to
recurrence by arm (treatment and control) over the 8-year follow-up period. The
y axis plots the risk of recurrence on a daily scale; thus, for example, the value
0.0002 represents an annualized 7.3% risk of an event (0.0002  365  0.073).
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Long-Term Recurrence Rates
Of the 20,898 patients, 11,615 were enrolled onto trials where the
median follow-up time exceeds 9 years. Figure 5 presents the recur-
rence rates, by 6-month intervals, to 15 years of follow-up. After 5
years, the recurrence rate by year never exceeds 1.5%, and after 8 years,
it never exceeds 0.5%.
DISCUSSION
These results illustrate the following three important concepts for the
management of early colon cancer: adjuvant FU-based treatment
actually eradicates colon cancer cells, thereby curing patients; late
relapses can occur, but after 8 years, the notion of cure is appropriate;
and most relapses occur in the first 2 years after surgery. These con-
cepts are relevant to our understanding of tumor biology, clinical
practice, and future clinical trial design.
A previous pooled analysis of FU-based adjuvant colon cancer
trials demonstrated a highly statistically significant 11% absolute
improvement in 5-year freedom from recurrence as a result of FU-































Fig 3. Disease-free survival hazard rates by time from random assignment and
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Fig 4. Continuous time estimate of the log-hazard ratios for (A) overall survival,
(B) disease-free survival, and (C) time to recurrence comparing treatment arm
with control arm over the 8-year follow-up period, with 95% pointwise CIs.
Values less than 0 indicate a benefit from treatment. For example, a value of
0.50 for the log-hazard ratio indicates a hazard ratio of 0.61 comparing
treatment with control at that time point (e–0.50  0.61), that is, a 39% reduction
in the risk of an event.
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patients, overall adjuvant therapy resulted in a 7% improvement in
8-year OS rate (5% in stage II patients and 10% in stage III patients).
Because the current analysis included two trials without FU/leucov-
orin or FU/levamisole chemotherapy arms, these survival improve-
ments likely underestimate the true survival benefit of FU and
leucovorin therapy. Importantly, in the current analysis, the hazard
rates of OS, DFS, and TTR in treated patients never exceed the corre-
sponding rates in untreated patients, at least in the 8-year follow-up
period reported here. The lack of any crossing of the hazard rate curves
indicates that adjuvant therapy is a curative intervention by intent. If
therapy simply delayed, as opposed to prevented, recurrences, we
would expect the TTR hazard rate for treated patients to eventually
exceed the rate in the untreated patients. Instead, the hazard rates
separate between 6 months and 2 years from random assignment, a
time perfectly compatible with the effect of chemotherapy. In addi-
tion, at least in the 8-year follow-up period, the fact that the OS hazard
rate in the treated patients remains lower than in the untreated pa-
tients supports the lack of a meaningful detrimental long-term effect
of FU-based chemotherapy, as measured by OS.
Itmaybeconsideredsurprisingthatsingle-agentFU-basedchem-
otherapy, which produces only a modest benefit in the advanced
disease setting (consistent response rate of 15%, progression-free sur-
vival time of 4 month, and median survival time of 11 to 12 months),
ultimately leads to an approximate 10% cure rate in the pooled pop-
ulation of high-risk stage II and III patients included in these trials
when used in the adjuvant setting. Biologic plausibility may tempt us
to extend this paradigm to combinations of newer cytotoxic drugs
(oxaliplatin and irinotecan) or to targeted agents such as bevacizumab
or cetuximab, and beyond (biologics). However, great caution must
be exercised. The results to date in the adjuvant setting demonstrate
that the paradigm of predicting activity in the adjuvant setting based
on studies in advanced disease works for combining oxaliplatin with
FU and leucovorin. On the basis of the results of the Adjuvant
Treatment of Colon Cancer (MOSAIC) trial,5 the 20% improve-
ment in response rate and 3 months of additional PFS time afforded
by infusional FU, leucovorin, and oxaliplatin compared with FU and
leucovorin in the advanced setting translate into an approximately
additional 7% gain in 3-year DFS in the adjuvant setting for stage III
patients. Recently, this early DFS improvement has translated into a
longer-term OS benefit after 6 years of follow-up.11 Our findings
suggest that this OS benefit will be maintained and may even grow
over time, because few late recurrences are to be expected. However,
although irinotecan combined with FU and leucovorin produces a
benefit similar to oxaliplatin with FU and leucovorin in the advanced
disease setting, this benefit has failed to translate into any significant
benefit when irinotecan is added to adjuvant FU and leucovorin.12,13
Therefore, the empirical data demonstrate that the paradigm that
efficacy in advanced disease leads to efficacy in the adjuvant setting is
indeed agent dependent. Extending this concept to other tumors, the
positive early experience with adjuvant trastuzumab in breast cancer14
and adjuvant imatinib in GI stromal cell tumors15 provides hope that
this paradigm will hold for biologic agents as well. More specifically,
this concept is relevant to the adjuvant therapy of colon cancer because
clinical trials using oxaliplatin with FU and leucovorin plus either
bevacizumab or cetuximab have completed or are about to complete
accrual or are ongoing (NSABP C-08; AVANT; E5202; Quick and
Simple and Reliable Collaborative Group-2: bevacizumab; NCCTG
N0147; and PETACC-8: cetuximab).16 However, the unique mecha-
nism of action of these biologic agents may require additional years of
follow-up before conclusions regarding a relapse-delaying versus a
curative effect of these complex treatments can be reliably ascertained.
It is possible that biologic agents such as angiogenesis inhibitors might
delay the occurrence of detectable metastatic disease without actually
eradicating tumor cells, thereby leading to improvements in early DFS
without affecting long-term OS.16 Regardless of the agent’s mecha-
nism of action, as survival after recurrence is extended by effective
therapy for metastatic disease, longer term follow-up is likely to be
required to establish a long-term survival benefit.17
Our results also provide valuable data to clinical practice regard-
ing the long-term risk of recurrence in patients with colon cancer who
undergo curative resection. We have previously demonstrated that
80% of colon cancer patients who experienced recurrence in the first 8
years after surgery do so in the first 3 years.7 These new results not only
confirm this finding, but also demonstrate that the risk of recurrence
continues to be low for up to 15 years of follow-up. On the basis of this
information, from a clinical trials perspective, there is little value in
mandating follow-up for recurrence beyond 5 years in future adjuvant
colon cancer trials. From a clinical perspective, once a patient has been
recurrence free for 5 years from surgery, continued medical care can
focus on other issues beyond the patient’s prior colon cancer such as
long-term adverse effects of the adjuvant therapy or secondary can-
cers, which are issues that may be more clinically relevant and preva-
lent in these patients.
Finally, these analyses clearly demonstrate that in untreated pa-
tients, the risk of recurrence is dominated by the early postsurgical
period, in particular the first 2 years. The clear major benefit of adju-
vant therapy is to significantly and meaningfully reduce this risk of
early recurrence by approximately 40%. From years 2 to 4, the TTR
and DFS rates remain slightly reduced in patients receiving adjuvant
therapy; however, the magnitude of benefit is clearly less than in the
early time period. Careful follow-up in the first 5 years for recurrence
is critical because an increasing number of patients found to have early
recurrence have the potential for cure by salvage surgery.18,19 The OS
hazard rate and HR plots (Figs 2A and 3A) indicate that this short-
term reduction in risk of recurrence translates into long-term advan-
tages in OS. As previously discussed,20 this early effect of adjuvant
chemotherapy could further reduce the required time to obtain rele-
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Fig 5. Risk of recurrence in each 6-month interval after random assignment
among patients remaining recurrence free at the start of each interval, by time.
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Continued analyses of large datasets, such as ACCENT, provide
valuable information that is useful to statisticians (eg, the adequacy of
statistical models), clinical trialists (eg, event rates over time), and
practicing oncologists (eg, surveillance patterns and prediction of cure
rates). The ACCENT group will continue to seek to include data from
all large randomized adjuvant colon cancer clinical trials to update
these findings from single-agent FU adjuvant studies with data from
current and next-generation treatment regimens.
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